We are live on ! Find out more
AVXL icon

Anavex Life Sciences

190 hedge funds and large institutions have $123M invested in Anavex Life Sciences in 2026 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 75 increasing their positions, 45 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

211% more call options, than puts

Call options by funds: $7.23M | Put options by funds: $2.33M

67% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 45

34% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 29

4% more funds holding

Funds holding: 183190 (+7)

0.93% more ownership

Funds ownership: 42.22%43.15% (+0.93%)

10% less capital invested

Capital invested by funds: $136M → $123M (-$13M)

Holders
190
Holders Change
+7
Holders Change %
+3.83%
% of All Funds
2.34%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
39
Increased
75
Reduced
45
Closed
29
Calls
$7.23M
Puts
$2.33M
Net Calls
+$4.91M
Net Calls Change
+$2.36M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$23.4M +$362K +83,488 +1%
State Street
2
State Street
Massachusetts
$13.9M +$557K +128,622 +3%
VCM
3
Vanguard Capital Management
Pennsylvania
$11.9M +$16.7M +3,863,950 New
Two Sigma Investments
4
Two Sigma Investments
New York
$9.97M +$6.9M +1,594,192 +96%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$6.72M +$716K +165,363 +8%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$3.06M +$2.41M +556,164 +127%
SF
7
Summit Financial
New Jersey
$2.89M +$161K +37,063 +4%
Bank of America
8
Bank of America
North Carolina
$2.65M +$1.47M +338,961 +65%
Goldman Sachs
9
Goldman Sachs
New York
$2.47M -$297K -68,533 -8%
VPM
10
Vanguard Portfolio Management
Pennsylvania
$2.4M +$3.39M +783,148 New
AQR Capital Management
11
AQR Capital Management
Connecticut
$2.32M +$2.63M +606,977 +405%
Charles Schwab
12
Charles Schwab
California
$2.32M +$379K +87,602 +13%
Northern Trust
13
Northern Trust
Illinois
$2.23M -$56.5K -13,055 -2%
Jane Street
14
Jane Street
New York
$2.23M -$190K -43,952 -6%
HF
15
HRT Financial
New York
$2.02M +$2.85M +657,877 New
VFT
16
Vanguard Fiduciary Trust
Pennsylvania
$1.99M +$2.8M +647,169 New
UBS Group
17
UBS Group
Switzerland
$1.75M +$479K +110,562 +24%
Citadel Advisors
18
Citadel Advisors
Florida
$1.72M +$1.93M +445,696 +392%
Barclays
19
Barclays
United Kingdom
$1.65M +$195K +45,105 +9%
Federated Hermes
20
Federated Hermes
Pennsylvania
$1.63M +$712K +164,411 +45%
PAG
21
Private Advisor Group
New Jersey
$1.53M +$346K +79,900 +19%
Marshall Wace
22
Marshall Wace
United Kingdom
$1.29M +$1.03M +237,307 +130%
LPL Financial
23
LPL Financial
California
$1.29M -$477K -110,142 -21%
Morgan Stanley
24
Morgan Stanley
New York
$1.1M -$507K -117,109 -25%
Renaissance Technologies
25
Renaissance Technologies
New York
$850K +$1.09M +251,378 +989%

AVXL Hedge Fund Activity: Q1 2026 in Review

190 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q1 2026, worth a combined $123M — down 9.6% from $136M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new AVXL positions and 29 closed out — a net gain of 10 holders — while 75 added to existing stakes and 45 trimmed.

The largest buyer was Two Sigma Investments, adding an estimated $6.9M. The largest seller was NWAM LLC, exiting entirely with an estimated $4.37M sold.

  • 190 institutional investors held Anavex Life Sciences (AVXL) as of Q1 2026, up from 183 in Q4 2025.
  • Funds reported $123M of Anavex Life Sciences stock for Q1 2026, down 9.6% quarter-over-quarter.
  • 39 funds opened new Anavex Life Sciences positions in Q1 2026 and 29 closed out, a net change of +10 holders.
  • The largest Anavex Life Sciences buyer in Q1 2026 was Two Sigma Investments, an estimated $6.9M added.
  • The largest Anavex Life Sciences seller in Q1 2026 was NWAM LLC, an estimated $4.37M sold.

Based on aggregated 13F filings for Q1 2026.